ClinicalTrials.gg
CompletedNCT01078389Updated Sep 10, 2014Results posted

Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout

A Phase 2 interventional study of Febuxostat and Placebo for Febuxostat in Joint Damage, sponsored by Takeda. Completed at 56 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-09-10.

Sponsored by Takeda · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.

Enrollment
8th of 29
314 · median 109
Started
2010
with 3 others
Phase 2
9 of 29
none open now
Registered
10th of 29
by date
Lead sponsor
11 of 29
Takeda

Among the 29 studies testing febuxostat in Gout, this one is the 8th largest by enrollment, is one of 4 that started in 2010, is one of 9 in phase 2, and was the 10th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:

About febuxostat

Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing febuxostat in Gout, or all of them as a file.
02

Study summary

This purpose of this study is to assess the effect of febuxostat, once daily (QD), on joint damage in patients with elevated serum urate levels and gout.

Read the detailed description

Gout is caused by high levels of uric acid in the body, and is associated with a broad range of comorbidities including heart disease, chronic kidney disease and additional risk factors like obesity and high blood pressure. Hyperuricemia, which is defined as an elevation in serum urate levels, develops into gout when urate crystals form from supersaturated body fluids and settle in joints and other organs. Urate-lowering therapy is used to treat hyperuricemia in patients with gout.

Current treatments focus on initiating urate-lowering therapy in hyperuricemic gout patients who have experienced multiple acute gout flares within the past year. However, joint damage caused by crystal deposition may occur much earlier than previously considered. Monosodium urate crystals have been found present in the joints of people with hyperuricemia who do not have any symptoms. The presence of monosodium urate crystals would indicate that after the crystals form, they stay within the joint if serum urate levels are not reduced. Lowering uric acid levels and maintaining them may reduce acute gout flare episodes and possibly halt or reduce joint damage in patients with gout.

This study will evaluate the effect of febuxostat on joint damage in hyperuricemic patients with early gout. All patients will receive gout flare prophylaxis for the first 6 months of the study. Gout flares may also be treated throughout the study.

A variety of imaging techniques are in use to evaluate gout. Plain radiographs (x-rays), Magnetic Resonance Imaging (MRI) and Dual Energy Computed Tomography (DECT) will be utilized in this study. The modified Sharp/Van Der Heijde scoring method (named after Drs. Sharp and Van Der Heijde) for assessment of x-rays has been validated in patients with chronic gout and will be used in this study for evaluating erosion and joint space narrowing. Participants are expected to have 15 visits which will include plain radiographic examinations at 5 visits, 3 Magnetic Resonance Imaging (MRI) examinations and 3 DECT procedures at selected sites.

03

Conditions studied

  • Joint Damage

Browse trials for

Keywords

  • Gout
  • Hyperuricemia
  • Uric Acid
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant, or the participant's legally acceptable representative, signs a written form/Health Insurance Portability \& Accountability Act (HIPAA) Authorization prior to the initiation of any study procedures.
  • Must have a history or presence of gout defined as having one or more of the following conditions of the American Rheumatism Association (ARA) preliminary criteria for the diagnosis of gout

    • A tophus proven to contain urate crystals by chemical or polarized light microscopic means and/or
    • Characteristic urate crystals in the joint fluid and/or
    • History of at least 6 of the following clinical, laboratory and x-ray phenomena*: *More than one flare criteria will be excluded for the purpose of this study if the participant has a history of only a single acute gout flare.

      • More than one attack of acute arthritis*
      • maximum inflammation developed within 1 day
      • monoarticular arthritis
      • redness observed over joints
      • first metatarsophalangeal joint painful or swollen
      • unilateral first metatarsophalangeal joint attack
      • unilateral tarsal joint attack
      • tophus (proven or suspected)
      • hyperuricemia
      • asymmetric swelling within a joint on x-ray
      • sub-cortical cysts without erosions on x-ray
      • joint fluid culture negative for organisms during attacks
    • *More than one flare criteria will be excluded for the purpose of this study if the participant has a history of only a single acute gout flare.
  • Is male and at least 18 years of age OR;

    • Female ≥45 years of age and at least 2 years AND has a Follicle Stimulating Hormone (FSH) level ≥40 IU/L OR
    • Female receiving hormone replacement therapy (HRT) must be ≥55 years of age (FSH level not required).
  • Has hyperuricemia defined as serum Uric Acid (sUA) level ≥7.0 mg/dL at Screening.
  • Has a history of ≤2 (1 or 2) flares. In participants with a history of 2 flares, must have had only one flare in any 12 month period. The primary affected joint will be based on the location of the first gout flare which must be located within right or left metatarsophalangeal (MTP), interphalangeal (IP), ankle, metacarpophalangeal (MCP), Proximal Inter-Phalangeal (PIP), or distal inter-phalangeal (DIP) joints prior to Screening.
  • Is capable of understanding and complying with protocol requirements, including scheduled clinic procedures.

Exclusion criteria

Exclusion Criteria:

  • Previously on urate-lowering therapy (allopurinol, febuxostat or probenecid).
  • Has secondary hyperuricemia (eg due to myeloproliferative disorder or organ transplant).
  • Has a history of xanthinuria.
  • Has a known to any component of the febuxostat formulation.
  • Has rheumatoid arthritis.
  • Has active peptic ulcer disease.
  • Has a history of cancer, except basal cell carcinoma of the skin, which has not been in remission for at least 5 years prior to the first dose of study medication.
  • Has experienced either a myocardial infarction (MI) or stroke within 90 days prior to the Screening visit.
  • Has (ALT) and/or aspartate aminotransferase (AST) values greater than 2.0 the during the Screening period.
  • Has a significant medical condition and/or conditions that would interfere with the treatment, safety or compliance with the protocol at the discretion of the Investigator.
  • Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse with 5 years prior to the Screening visit. Participant consumes >14 alcoholic beverages/week.
  • Has received any medicinal product within 30 days prior to the Screening visit. In addition, the participant has been previously randomized into this study and received at least one dose of double blind study drug treatment.
  • Has an estimated (eGFR) \<60 mL/min calculated using the Modification of Diet in Renal Disease (MDRD) formula by the Central Laboratory.
  • Has a serum creatinine at Screening greater than 2.0 mg/dL.
  • Has a known history of infection with , or .
  • Is a study site employee, or is an immediate family member (ie, spouse, parent, child, and sibling) of a study site employee involved in conduct of this study.
  • Is unable to understand verbal or written English or any other language for which a certified translation of the approved form is available.
  • Is required to take excluded medications.
  • Magnetic Resolution Imaging:

    • Has a known hypersensitivity to gadolinium
    • Has history of severe asthma
    • Has an electronically, magnetically or mechanically activated implanted device
    • Has any object that could present a potential hazard or interfere with MRI interpretation secondary to the artifact (i.e. metallic foreign bodies)
    • Has a significant medical condition considered by the Investigator (or radiologist) to interfere with the participant's ability to receive gadolinium (eg Sickle cell anemia).
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
314 participants (actual)

Study arms

  • Experimental
    Febuxostat 40 mg or 80 mg

    Febuxostat 40 mg or 80 mg (based on serum urate levels at Day 14), capsules, orally, once daily for up to 24 Months.

    Drug: Febuxostat

  • Placebo comparator
    Placebo

    Febuxostat placebo-matching capsules, orally, once daily for up to 24 Months.

    Drug: Placebo for Febuxostat

Interventions

  • Febuxostat capsules

    Also known as: Uloric, TMX-67

  • DrugPlacebo for Febuxostat

    Febuxostat placebo-matching capsules

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint

    The single affected joint was defined as the joint with the history of the first acute gout flare. Radiographs (X-rays) of this single joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst). Individual erosion scores were summed to a maximum erosion score of 5 for joints in the hands and 10 for joints in the feet. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.

    Time frame: Baseline and Month 24

Secondary outcomes

  1. Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Total Scores From Full Hands and Feet Radiographs

    Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320. Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst) for a total JSN score range of 0 to 208. The Erosion Score and the JSN Score were combined for a total possible score of 0 to 528. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.

    Time frame: Baseline and Month 24

  2. Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Scores From Full Hands and Feet Radiographs

    Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.

    Time frame: Baseline and Month 24

  3. Mean Change From Baseline to Month 24 in the Rheumatoid Arthritis MRI Scoring System (RAMRIS) Score of the Single Affected Joint

    The single affected joint was defined as the joint with the history of the first acute gout flare. Magnetic Resonance Imaging (MRI) was evaluated using the Rheumatoid Arthritis MRI Score (RAMRIS). Bone erosion in the proximal and distal location were each assessed in the affected joint using an 11-point scale where 0=no erosion (best) to 10=91-100% bone eroded (worst) for a bone erosion score range of 0 to 20. Bone marrow edema in the proximal and distal location were each assessed using a 4-point scale where 0=no edema (best) to 3=67-100% edema (worst) for a bone marrow edema (BME) score range of 0 to 6. Synovitis was assessed in the affected joint using a 4-point scale where 0=normal (best) to 3=severe (worst). Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.

    Time frame: Baseline and Month 24

  4. Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Total Score of the Single Affected Joint

    The single affected joint was defined as the joint with the history of the first acute gout flare. Radiographs (X-rays) of the single affected joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) and Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst). The Erosion Score and the JSN Score were summed for the Total Score. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.

    Time frame: Baseline and Month 24

07

Results

Posted Sep 10, 2014

Participant flow

Participants took part in the study at 65 investigative sites in the United States from 10 March 2010 to 3 September 2013.

Participant flow — Overall Study
MilestoneFebuxostat 40 mg or 80 mgPlacebo
Started157157
Completed9390
Not completed6467
Withdrew: Adverse event106
Withdrew: Major protocol deviation20
Withdrew: Lost to follow-up2323
Withdrew: Voluntary withdrawal2036
Withdrew: Other92

Outcome measures

PrimaryMean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint

The single affected joint was defined as the joint with the history of the first acute gout flare. Radiographs (X-rays) of this single joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst). Individual erosion scores were summed to a maximum erosion score of 5 for joints in the hands and 10 for joints in the feet. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.

Time frame:
Baseline and Month 24
Reported as:
Mean · score on a scale
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint
score on a scaleFebuxostat 40 mg or 80 mgPlacebo
Baseline0.16 ± 0.4440.11 ± 0.438
Change from Baseline at Month 240.01 ± 0.3300.01 ± 0.248
Statistical analysis
  • Febuxostat 40 mg or 80 mg vs Placebo · Ranked Analysis of Covariance (ANCOVA) · p = 0.472Baseline modified Sharp/van der Heijde Erosion Score as a covariate.
SecondaryMean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Total Scores From Full Hands and Feet Radiographs

Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320. Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst) for a total JSN score range of 0 to 208. The Erosion Score and the JSN Score were combined for a total possible score of 0 to 528. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.

Time frame:
Baseline and Month 24
Reported as:
Mean · score on a scale
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Total Scores From Full Hands and Feet Radiographs
score on a scaleFebuxostat 40 mg or 80 mgPlacebo
Baseline4.98 ± 9.7074.56 ± 8.631
Change from Baseline at Month 24 (n=78,74)0.31 ± 2.4470.29 ± 1.746
Statistical analysis
  • Febuxostat 40 mg or 80 mg vs Placebo · Ranked ANCOVA · p = 0.548Baseline modified Sharp/van der Heijde Total Score from full hands and feet as a covariate.
SecondaryMean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Scores From Full Hands and Feet Radiographs

Radiographs (X-rays) of 40 joints in the hands and 12 joints in the feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) for a total erosion score range of 0 to 320. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.

Time frame:
Baseline and Month 24
Reported as:
Mean · score on a scale
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Scores From Full Hands and Feet Radiographs
score on a scaleFebuxostat 40 mg or 80 mgPlacebo
Baseline0.36 ± 1.1600.17 ± 0.473
Change from Baseline at Month 24 (n=78,74)0.17 ± 1.7090.11 ± 0.969
Statistical analysis
  • Febuxostat 40 mg or 80 mg vs Placebo · Ranked ANCOVA · p = 0.389Baseline modified Sharp/van der Heijde Erosion Score from full hands and feet as a covariate.
SecondaryMean Change From Baseline to Month 24 in the Rheumatoid Arthritis MRI Scoring System (RAMRIS) Score of the Single Affected Joint

The single affected joint was defined as the joint with the history of the first acute gout flare. Magnetic Resonance Imaging (MRI) was evaluated using the Rheumatoid Arthritis MRI Score (RAMRIS). Bone erosion in the proximal and distal location were each assessed in the affected joint using an 11-point scale where 0=no erosion (best) to 10=91-100% bone eroded (worst) for a bone erosion score range of 0 to 20. Bone marrow edema in the proximal and distal location were each assessed using a 4-point scale where 0=no edema (best) to 3=67-100% edema (worst) for a bone marrow edema (BME) score range of 0 to 6. Synovitis was assessed in the affected joint using a 4-point scale where 0=normal (best) to 3=severe (worst). Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.

Time frame:
Baseline and Month 24
Reported as:
Mean · score on a scale
Mean Change From Baseline to Month 24 in the Rheumatoid Arthritis MRI Scoring System (RAMRIS) Score of the Single Affected Joint
score on a scaleFebuxostat 40 mg or 80 mgPlacebo
Synovitis:Baseline (BL)(n=82,76)1.29 ± 0.7821.09 ± 0.687
Synovitis:Change from Baseline (n=75,67)-0.43 ± 0.713-0.07 ± 0.531
Erosion (Distal+Proximal):Baseline (n=84,77)1.63 ± 0.9351.48 ± 0.916
Erosion (Distal+Proximal):Change from BL(n=79,69)-0.01 ± 0.7020.04 ± 0.475
Edema (Distal+Proximal):Baseline (BL) (n=81,75)0.73 ± 1.0220.51 ± 0.919
Edema (Distal+Proximal):Change from BL(n=77,66)-0.36 ± 0.916-0.10 ± 0.962
Statistical analysis
  • Febuxostat 40 mg or 80 mg vs Placebo · Ranked ANCOVA · p = <0.001Baseline RAMRIS Synovitis Score as a covariate.
  • Febuxostat 40 mg or 80 mg vs Placebo · Ranked ANCOVA · p = 0.634Baseline RAMRIS Erosion(Distal+Proximal) Score as a covariate.
  • Febuxostat 40 mg or 80 mg vs Placebo · Ranked ANCOVA · p = 0.307Baseline RAMRIS Edema(Distal+Proximal) Score as a covariate.
SecondaryMean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Total Score of the Single Affected Joint

The single affected joint was defined as the joint with the history of the first acute gout flare. Radiographs (X-rays) of the single affected joint in the hands or feet were evaluated using the modified Sharp/van der Heijde method. Each erosion was assessed using a 4-point scale where 0=no erosions (best) to 3=large erosion passing the mid-line (worst) and Joint space narrowing (JSN) was assessed using a 5-point scale where 0=normal (best) to 4=absence of joint space, presumptive evidence of ankyloses, or complete luxation (worst). The Erosion Score and the JSN Score were summed for the Total Score. Higher scores indicated more joint damage. A negative change from Baseline indicated improvement.

Time frame:
Baseline and Month 24
Reported as:
Mean · score on a scale
Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Total Score of the Single Affected Joint
score on a scaleFebuxostat 40 mg or 80 mgPlacebo
Baseline0.85 ± 1.0570.77 ± 1.022
Change from Baseline at Month 24(n=81,76)0.00 ± 0.6020.05 ± 0.361
Statistical analysis
  • Febuxostat 40 mg or 80 mg vs Placebo · Ranked ANCOVA · p = 0.122Baseline modified Sharp/van der Heijde Total Score as a covariate.

Adverse events

Collected over Treatment-emergent adverse events are adverse events, regardless of relationship to study drug, that started on or after the first dose of study drug and no more than 30 days after last dose of study drug (Up to 25 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Febuxostat 40 mg or 80 mg—13/157 (8.3%)73/157 (46.5%)
Placebo—11/157 (7%)67/157 (42.7%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventFebuxostat 40 mg or 80 mgPlacebo
DyspnoeaRespiratory, thoracic and mediastinal disorders0/1572/157
Cardiac failure congestiveCardiac disorders1/1571/157
Acute myocardial infarctionCardiac disorders1/1570/157
Angina pectorisCardiac disorders1/1570/157
Mitral valve incompetenceCardiac disorders0/1571/157
Left ventricular dysfunctionCardiac disorders0/1571/157
Atrial fibrillationCardiac disorders0/1571/157
Ventricular fibrillationCardiac disorders0/1571/157
Vitreous haemorrhageEye disorders0/1571/157
Diabetic retinopathyEye disorders0/1571/157
Most frequent other events
Showing 10 of 13
Most frequent other events
EventFebuxostat 40 mg or 80 mgPlacebo
Upper respiratory tract infectionInfections and infestations15/15716/157
ArthralgiaMusculoskeletal and connective tissue disorders14/15710/157
Pain in extremityMusculoskeletal and connective tissue disorders9/15713/157
Aspartate aminotransferase increasedInvestigations11/1576/157
Blood creatine phosphokinase increasedInvestigations9/15711/157
Alanine aminotransferase increasedInvestigations10/1576/157
HeadacheNervous system disorders5/15710/157
DiarrhoeaGastrointestinal disorders9/1576/157
Gamma-glutamyltransferase increasedInvestigations6/1579/157
Back painMusculoskeletal and connective tissue disorders9/1576/157

Baseline characteristics

Age, Continuous
Age, Continuous(years)Febuxostat 40 mg or 80 mgPlaceboTotal
Mean51.4 ± 12.3650.1 ± 11.7250.8 ± 12.04
Age, Customized
Age, Customized(participants)Febuxostat 40 mg or 80 mgPlaceboTotal
<45 years494291
45 to <65 years8599184
≥65 years231639
Sex: Female, Male
Sex: Female, Male(Participants)Febuxostat 40 mg or 80 mgPlaceboTotal
Female141226
Male143145288
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Febuxostat 40 mg or 80 mgPlaceboTotal
American Indian or Alaska Native101
Asian81018
Black or African American252449
Native Hawaiian or Other Pacific Islander101
White119121240
Other325
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Febuxostat 40 mg or 80 mgPlaceboTotal
Hispanic or Latino263662
Not Hispanic or Latino131121252
Region of Enrollment
Region of Enrollment(participants)Febuxostat 40 mg or 80 mgPlaceboTotal
United States157157314
Height
Height(cm)Febuxostat 40 mg or 80 mgPlaceboTotal
Mean176.3 ± 9.22176.5 ± 8.36176.4 ± 8.79
Weight
Weight(kg)Febuxostat 40 mg or 80 mgPlaceboTotal
Mean102.8 ± 20.88100.7 ± 21.20101.7 ± 21.04

5 further baseline measures are reported on the registry.

08

Study locations

56 sites
  • Mesa, Arizona, United States
  • Tucson, Arizona, United States
  • Burbank, California, United States
  • Carmichael, California, United States
  • Costa Mesa, California, United States
  • Irvine, California, United States
  • Orange, California, United States
  • Rancho Cucamonga, California, United States
  • San Diego, California, United States
  • San Luis Obispo, California, United States
  • Trumbull, Connecticut, United States
  • Boynton Beach, Florida, United States
  • Daytona Beach, Florida, United States
  • Fort Lauderdale, Florida, United States
  • Hialeah, Florida, United States
  • Miami, Florida, United States
  • Sanford, Florida, United States
  • Tampa, Florida, United States
  • Winter Park, Florida, United States
  • Honolulu, Hawaii, United States
  • Arlington Heights, Illinois, United States
  • Avon, Indiana, United States
  • Greenfield, Indiana, United States
  • Wichita, Kansas, United States
  • Rockport, Maine, United States
  • Chaska, Minnesota, United States
  • Belzoni, Mississippi, United States
  • Olive Branch, Mississippi, United States
  • Billings, Montana, United States
  • Missoula, Montana, United States
  • Bellevue, Nebraska, United States
  • Henderson, Nevada, United States
  • Las Vegas, Nevada, United States
  • Albuquerque, New Mexico, United States
  • Charlotte, North Carolina, United States
  • Lenoir, North Carolina, United States
  • Shelby, North Carolina, United States
  • Dayton, Ohio, United States
  • Franklin, Ohio, United States
  • Willoughby Hills, Ohio, United States
  • Oklahoma City, Oklahoma, United States
  • Eugene, Oregon, United States
  • Duncansville, Pennsylvania, United States
  • East Providence, Rhode Island, United States
  • Columbia, South Carolina, United States
  • Rapid City, South Dakota, United States
  • Kingsport, Tennessee, United States
  • Austin, Texas, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Southlake, Texas, United States
  • Sugar Land, Texas, United States
  • Arlington, Virginia, United States
  • Burke, Virginia, United States
  • Manassas, Virginia, United States
  • Kenosha, Wisconsin, United States
09

References and documents

Publications

  • Dalbeth N, Saag KG, Palmer WE, Choi HK, Hunt B, MacDonald PA, Thienel U, Gunawardhana L. Effects of Febuxostat in Early Gout: A Randomized, Double-Blind, Placebo-Controlled Study. Arthritis Rheumatol. 2017 Dec;69(12):2386-2395. doi: 10.1002/art.40233. PubMed 28975718 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2010
First posted
Mar 2, 2010
Start
Mar 2010
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Results first posted
Sep 10, 2014
Last update
Sep 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01078389
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Mar 2, 2010
Start date
Mar 2010
Primary completion
Sep 2013
Completion
Sep 2013
Results posted
Sep 10, 2014
Last update
Sep 10, 2014

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion